<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490216</url>
  </required_header>
  <id_info>
    <org_study_id>3002-11961-00006857</org_study_id>
    <nct_id>NCT01490216</nct_id>
  </id_info>
  <brief_title>Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence</brief_title>
  <official_title>Open-Label Pilot Study of Lisdexamfetamine for Treatment of Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate ideal dose or lisdexamfetamine and tolerability,
      plus reduction in cocaine use and craving.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate ideal dose or lisdexamfetamine and tolerability, plus reduction in cocaine use and
      craving as determined by self-report and cocaine-positive urine samples.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum total lisdexamfetamine dose achieved during the study period defined as the highest amount of medication per day maintained for a seven day period</measure>
    <time_frame>Study weeks 3-6</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>lisdexamfetamine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>open label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lisdexamfetamine</intervention_name>
    <description>20mg q.d. to 70mg b.i.d</description>
    <arm_group_label>lisdexamfetamine</arm_group_label>
    <other_name>vyvanse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        .Inclusion Criteria:

          1. Men and women between the ages of 18-65 who meet Diagnostic and Statistical Manual -IV
             criteria for current cocaine dependence

          2. Used cocaine at least four days in the past month

          3. Individuals must be in good general health

          4. Individuals must be capable of giving informed consent and capable of complying with
             study procedures

          5. Women of child-bearing age must agree to use a method of contraception with proven
             efficacy, consisting of one of the following: 1) Any form of hormonal contraception;
             2) Intra-uterine device; 3) Sterilization; 4) Double-barrier contraception which is a
             combination of two of the following: condoms, spermicide, diaphragm. Pregnancy tests
             will be performed monthly and if a woman becomes pregnant, the study medication will
             be discontinued.

        Exclusion Criteria:

          1. Individuals who meet DSM-IV-TR criteria for bipolar disorder, schizophrenia, or any
             psychotic disorder other than transient psychosis due to drug abuse

          2. Individuals with any other current Axis I psychiatric disorder as defined by DSM-IV-TR
             that in the investigator's judgment are unstable, or would be disrupted by study
             medication, or are likely to require pharmacotherapy during the study period

          3. Individuals physiologically dependent on any other drugs (excluding nicotine or
             cannabis) which require medical intervention

          4. Individuals with current psychostimulant abuse or dependence (other than cocaine
             dependence)

          5. Individuals with current suicidal risk

          6. Individuals with coronary vascular disease as indicated by history or suspected by
             abnormal ECG or history of cardiac symptoms

          7. Unstable physical disorders which might make participation hazardous such as
             uncontrolled hypertension (SBP &gt; 140, diastolic blood pressure &gt; 90, or heart rate &gt;
             100 when sitting quietly), acute hepatitis (patients with chronic mildly elevated
             transaminases (&lt; 3x upper limit of normal are acceptable), or uncontrolled diabetes

          8. Individuals with a history of seizures, hyperthyroidism and/or glaucoma

          9. History of allergic reaction to study medication

         10. Women who are pregnant or nursing

         11. Currently being prescribed psychotropic medication by another physician (other than
             sleep medication)

         12. Individuals who are legally mandated (e.g., to avoid incarceration) to participate in
             substance abuse treatment program
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc E Mooney, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2011</study_first_posted>
  <last_update_submitted>November 12, 2013</last_update_submitted>
  <last_update_submitted_qc>November 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cocaine</keyword>
  <keyword>lisdexamfetamine</keyword>
  <keyword>vyvanse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 22, 2018</submitted>
    <returned>February 15, 2018</returned>
    <submitted>February 16, 2018</submitted>
    <returned>March 16, 2018</returned>
    <submitted>April 25, 2018</submitted>
    <returned>May 22, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

